Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302840 | 0.92 | ALDH1A1 (0.38) | CYP2C9GAAALDH1A1POLBPKM | |
| SCHEMBL3298728 | 0.90 | PTGDR2 (0.45) | CYP2C9ALDH1A1POLBPKMSMN1; SMN2 | |
| SCHEMBL3296315 | 0.89 | SMN1; SMN2 (0.41) | ALDH1A1POLBPKMSMN1; SMN2 | |
| SCHEMBL2769893 | 0.86 | PTGDR2 (0.44) | CYP2C9ALDH1A1SMN1; SMN2PTGDR2TSHR | |
| SCHEMBL3299216 | 0.82 | PTGDR2 (0.45) | GAAALDH1A1POLBPKMPTGDR2 | |
| SCHEMBL3297889 | 0.80 | POLB (0.36) | CYP2C9GAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2771887 | 0.79 | PTGDR2 (0.47) | GAAALDH1A1POLBPKMSMN1; SMN2 | |
| SCHEMBL3302365 | 0.76 | POLB (0.42) | GAAALDH1A1POLBPKMSMN1; SMN2 | |
| SCHEMBL2768490 | 0.75 | PTGDR2 (0.55) | CYP2C9PTGDR2 | |
| SCHEMBL3564465 | 0.75 | PTGDR2 (0.52) | CYP2C9GAAALDH1A1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2121686-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078069-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | HRH2, HRH4, HRH1 | CYP2C9 2206/4885GAA 4583/4885ALDH1A1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.